Table 1. Patient characteristics.
| CDI arm (N=75) | CTI arm (N=74) | |
|---|---|---|
| Age, years | 54.5 (23–74) | 51.2 (23–74) |
| Sex | ||
| Male | 46 (61%) | 45 (61%) |
| Female | 29 (39%) | 29 (39%) |
| ECOG-PS | ||
| 0 | 52 (69%) | 51 (69%) |
| 1 | 15 (20%) | 17 (23%) |
| 2 | 3 (4%) | 3 (4%) |
| Not reported | 5 (7%) | 3 (4%) |
| Disease site | ||
| M1a–M1b | 35 (47%) | 35 (47%) |
| M1c | 40 (53%) | 39 (53%) |
| LDH level | ||
| Abnormal | 22 (29%) | 21 (28%) |
| Normal | 53 (71%) | 53 (72%) |
| Time from diagnosis to metastatic disease, months | 32.3 (1.8–164.9) | 23.2 (0–159.7) |
Abbreviations: CDI=DTIC-based chemotherapy; CTI=TMZ-based chemotherapy; DTIC=Dacarbazine; ECOG-PS=Eastern Cooperative Oncology Group performance status; LH=lactate dehydrogenase; TMZ=Temozolomide.
Data are N (%) or median (range).